Real-world data on persons living with HIV (PLWH) switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) while virologically suppressed: 96-week data from the Icona cohort

被引：0
|
作者：
Monforte, A. d'Arminio [1 ]
Tavelli, A. [1 ]
Cingolani, A. [2 ,3 ]
Taramasso, L. [4 ]
Mussini, C. [5 ]
Piconi, S. [6 ]
Calcagno, A. [7 ,8 ]
Orofino, G. [9 ]
Cicalini, S. [10 ]
Castagna, A. [11 ,12 ]
Ceccherini-Silberstein, F. [13 ]
Gori, A. [14 ,15 ]
Guaraldi, G. [5 ]
Antinori, A. [10 ]
机构：
[1] Icona Fdn, Milan, Italy
[2] Fdn Policlin Univ Agostino Gemelli IRCCS, Infect Dis Unit, Rome, Italy
[3] Univ Cattolica Sacro Cuore, Dept Safety & Bioeth, Rome, Italy
[4] Univ Genoa, Osped Policlin San Martino IRCCS, Unit Infect Dis, Genoa, Italy
[5] Univ Modena & Reggio Emilia, AOU Modena, Infect & Trop Dis Unit, Modena, Italy
[6] ASST Lecco, Infect Dis Unit, Lecce, Italy
[7] Osped Amedeo Savoia, Unit Infect Dis, Turin, Italy
[8] Univ Turin, Dept Med Sci, Turin, Italy
[9] ASL Citta Torino, Div A Infect Dis, Osped Amedeo Savoia, Turin, Italy
[10] Natl Inst Infect Dis Lazzaro Spallanzani IRCCS, Clin Dept HIV, AIDS Unit, Rome, Italy
[11] IRCCS San Raffaele Sci Inst, Infect Dis Unit, Milan, Italy
[12] Univ Vita Salute San Raffaele, Milan, Italy
[13] Univ Roma Tor Vergata, Dept Expt Med, Rome, Italy
[14] ASST Fatebenefratelli Sacco, Unit Infect Dis 2, Milan, Italy
[15] Univ Milan, Milan, Italy
来源：
HIV MEDICINE | 2023年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
843
引用
收藏
页码：157 / 159
页数：3
相关论文
共 48 条
  • [21] Real-world data on metabolic profile and renal function in a Latin American cohort of people living with HIV starting or switching to bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination: 48-week follow-up
    Cecchini, D. M.
    Mauas, R.
    Copertari, G.
    Brizuela, M.
    Bacelar, B.
    Castro, G.
    Diana Menendez, S.
    Bottaro, E.
    Cassetti, I.
    HIV MEDICINE, 2023, 24 : 112 - 112
  • [22] The effects of switching from dolutegravir/abacavir/lamivudine to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV on neuropsychiatric symptoms: preliminary findings from a randomised study
    Rossetti, B.
    Ferrara, M.
    Taramasso, L.
    Bai, F.
    Lombardi, F.
    Ciccarelli, N.
    Durante, M.
    Alladio, F.
    Rancan, I.
    Montagnani, F.
    Di Biagio, A.
    Monforte, A. d'Arminio
    Zazzi, M.
    Fabbiani, M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 161 - 162
  • [23] Immuno-virological and Clinical Follow-up of Persons Living With HIV-2 (PWHIV-2) Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate (BIC/FTC/TAF): A Retrospective Study
    Joly, Veronique
    Ferre, Valentine M.
    Le Hingrat, Quentin
    Peytavin, Gilles
    Cresta, Melanie
    Charpentier, Charlotte
    Digumber, Marc
    Damond, Florence
    Yazdanpanah, Yazdan
    Matheron, Sophie
    Descamps, Diane
    Ghosn, Jade
    CLINICAL INFECTIOUS DISEASES, 2024,
  • [24] Effectiveness, safety and tolerability of dolutegravir/lamivudine versus tenofovir alafenamide/emtricitabine/bictegravir in a real-life cohort of HIV-1 virologically suppressed treatment experienced people living with HIV
    Tordi, S.
    De Socio, G. V.
    Altobelli, D.
    Gidari, A.
    Zoffoli, A.
    Francisci, D.
    HIV MEDICINE, 2023, 24 : 153 - 155
  • [25] Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials
    Avihingsanon, Anchalee
    Chetchotisakd, Ploenchan
    Kiertiburanakul, Sasisopin
    Ratanasuwan, Winai
    Siripassorn, Krittaecho
    Supparatpinyo, Khuanchai
    Martin, Hal
    Wang, Hui
    Wong, TinHung
    Wang, Hsiu Yin
    HIV MEDICINE, 2023, 24 (03) : 290 - 300
  • [26] Real-world data on the use of the antiretroviral treatment (ART) regimen tenofovir alafenamide/emtricitabine/darunavir/cobicistat (TAF/FTC/DRV/c) and dolutegravir (DTG)
    Keane, A.
    Kelly, L.
    Keegan-Hickey, C.
    White, A.
    Heekin, A.
    Farrell, G.
    Moriarty, M.
    Devitt, E.
    Villa, G.
    HIV MEDICINE, 2023, 24 : 378 - 379
  • [27] Patient-reported outcomes among people living with HIV on bictegravir/ emtricitabine/tenofovir alafenamide fixed-dose combination: Real-world data from Latin America
    Cecchini, D. M.
    Seleme, S.
    Mingrone, M. V.
    Diana Menendez, S.
    Mauas, R.
    Bottaro, E.
    Cassetti, I.
    HIV MEDICINE, 2023, 24 : 414 - 414
  • [28] Patient-reported outcome measures at 12 months in a real-world cohort of people living with HIV receiving bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Europe, Canada, and Israel
    Brunetta, Jason
    Monforte, Antonella
    van Welzen, Berend
    Milinkovic, Ana
    Marongiu, Andrea
    Heinzkill, Marion
    Thorpe, David
    Cornejo, Almudena Torres
    Antela, Antonio
    HIV MEDICINE, 2022, 23 : 76 - 76
  • [29] Real-life data of immune recovery using Bictegravir/Emtricitabine/Tenofovir Alafenamide in virologically suppressed people living with HIV. Results at 48-96 weeks of RETROBIC Study (Vol 79, Pg 595, 2024)
    Troya, Jesus
    Pousada, Guillermo
    Mican, Rafael
    Galera, Carlos
    Sanz, Jose
    de los Santos, Ignacio
    Duenas, Carlos
    Cabello, Noemi
    Martin, Cristina
    Galindo, Maria Josefa
    Garcinuno, Maria Angeles
    Pedrero-Tome, Roberto
    Buzon, Luis
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (09) : 2406 - 2410
  • [30] Treatment initiation or switch to BIC/FTC/TAF - real-world safety and efficacy data from two HIV centers in Romania
    Sandulescu, Oana
    Irimia, Madalina
    Benea, Otilia Elisabeta
    Mardarescu, Mariana
    Preotescu, Liliana Lucia
    Dorobat, Carmen Mihaela
    Loghin, Isabela Ioana
    Nicolau, Irina Cristina
    Jipa, Raluca Elena
    Popescu, Ramona Stefania
    Benea, Cristina Loredana
    Cozma, Alina
    Daramus, Ioana Andreea
    Miron, Victor Daniel
    Prisacariu, Liviu Jany
    Bahna, Adriana Florina
    Nistor, Irina
    Secrieru, Oana Manuela
    George, Silvas
    Birca, Andreea
    Dobrea, Loredana
    Sogorescu, Alexandra-Stefana
    Viziteu, Ioana
    Streinu-Cercel, Anca
    GERMS, 2021, 11 (04): : 512 - 522
12345